Navigation Links
Combination of Key Nutrients Reduces Stress and Emotional Problems in Those with Attention Deficit Hyperactivity Disorder (ADHD) Research Shows
Date:2/11/2013

WICHITA, Kan., Feb. 11, 2013 /PRNewswire-USNewswire/ -- Attention deficit hyperactivity disorder (ADHD) affects approximately two million American children, and this condition has grown to become the most commonly diagnosed behavioral disorder of childhood. The cause of ADHD is generally acknowledged to be multifactorial, involving both biological and environmental influence.

Nutritional deficiencies, including deficiencies in fatty acids (EPA, DHA), the amino acid methionine, and the trace minerals zinc and selenium, have been shown to influence neuronal function and produce defects in neuronal plasticity, as well as impact behavior in children with attention deficit hyperactivity disorder. These nutritional disturbances or variations from reference values have been associated with behavior typical of ADHD.

The investigation was undertaken to determine the reference values of specific biochemical markers that have been associated with behavior typical of ADHD in a group of patients before and after metabolic correction.

The study was based on data extracted from the Riordan Clinic's patient history database covering a period of over ten years. Researchers performed laboratory tests in 116 patients 2.7-25 years old with a diagnosis of ADHD, and compared the distributions of fatty acids, essential metals, and the levels of metabolic stress factors with established reference ranges before and after interventions. In addition, the association between toxic metal concentrations and the levels of essential metals in these patients was analyzed.

Treatment of ADHD patients was performed according to principles of integrative management of this condition, and patients were treated by essential fatty acids, amino acids, minerals, probiotics and vitamins.

"According to our data, the metabolic correction of ADHD by supplementation can ameliorate ADHD symptoms. Eighty percent (80%) of children who were treated from several weeks to 1-2 years, demonstrated improvement of metabolic stress level, measured by pyrrole test. For these patients, the levels of EPA were increased and the omega-6/omega-3 ratio was improved," states Dr. Nina Mikirova , Director of Research at the Riordan Clinic.

Putting all data together, it was demonstrated that after consumption of a combination of fatty acids as well as magnesium and zinc, amino acids, vitamins and probiotics, most subjects had a considerable reduction in markers of metabolic stress and reported less emotional problems.

Further studies need to be conducted with integrative metabolic correction therapy to determine its value in the management of ADHD.

This research, conducted by Riordan Clinic scientists Mikirova NA, Rogers AM, Taylor PR, Hunninghake RE, in collaboration with scientists from the School of Public Health, Medical Sciences Campus of the University of Puerto Rico, Miranda-Massari JR, and Gonzalez MJ, has recently been published in the Journal of Functional Foods in Health and Disease as "Metabolic correction for attention deficit/hyperactivity disorder: A biochemical-physiological therapeutic approach."

The full text of the article can be found at http://functionalfoodscenter.net/files/63028864.pdf. To read this and other articles written by Riordan Clinic researchers, go to http://www.riordanclinic.org/research/journal-articles.shtml.

Riordan Clinic (http://riordanclinic.org) is a progressive nutrition-based medical clinic and a 501c3 nonprofit organization established in 1975 in Wichita Kansas.  It is comprised of a CLIA Certified laboratory, Bio-Center Laboratory; an orthomolecular clinic specializing in the treatment of chronic disease; a library registered with the National Libraries of Medicine; and a research division specializing in the study of nutritional remedies, degenerative and chronic disease, and analytical method development.  For more information call Dr. Nina Mikirova 316-682-3100 or email: nmikirova@riordanclinic.org.


'/>"/>
SOURCE Riordan Clinic
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. A Phase IIa Interferon Free Combination Hepatitis C Trial of Simeprevir (TMC435) and TMC647055 Will Commence Shortly
2. Syndax Pharmaceuticals Announces Start of Phase 1/2 Study of Entinostat in Combination with Lapatinib in HER2-Positive Metastatic Breast Cancer
3. Jennerex Announces First Patient Treated in Phase 1/2 Clinical Trial of JX-594 in Combination with Irinotecan in Patients with Metastatic Colorectal Cancer
4. New nano-material combinations produce leap in infrared technology
5. Argos Therapeutic Arcelis™ Immunotherapy AGS-003 in Combination With Sunitinib Shows Statistically Significant Correlation of Immune System Response to Overall Survival in Phase 2 Study in Patients with Advanced Renal Cell Carcinoma (RCC)
6. Metabolex Announces Positive Results From its Clinical Study of Arhalofenate in Combination With Febuxostat
7. NKTR-102 Demonstrates Synergistic Anti-Tumor Activity in Combination with Pegylated Liposomal Doxorubicin in Platinum-Resistant Ovarian Cancer
8. University of Colorado Cancer Center Study Finds That Body's Ibuprofen, SPARC, Reduces Inflammation and Thus Bladder Cancer Development and Metastasis
9. Vaccination reduces the risk of unvaccinated badger cubs testing tuberculosis positive
10. Phase II Data Presented at ACNP 2012 Shows Novel Antidepressant GLYX-13 Significantly Reduces Depression Scores Within Hours
11. Computer vision reduces risk in clinical trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... N.C. , Feb. 5, 2016  In the ... role for a host of launch activities including the ... of this launch activity is especially high in the ... Best Practices and the Role of Medical ... help companies focused on oncology therapies find better ways ...
(Date:2/4/2016)... - New FDA action date of July 22, ... July 22, 2016   --> - ...   - Lifitegrast has the potential to be the ... signs and symptoms of dry eye disease in adults ... product approved in the U.S. in the past decade indicated for the treatment of ...
(Date:2/4/2016)... 2016  CytoSorbents Corporation (NASDAQ: CTSO ), ... CytoSorb® blood filter to treat deadly inflammation in ... announced that CEO Dr. Phillip Chan , ... Group,s 2016 Disruptive Growth & Healthcare Conference, providing ... Conference Presentation Details: Where: Convene Conference ...
(Date:2/4/2016)... Sinovac Biotech Ltd. ("Sinovac" or the "Company") ... products in China , today announced ... received on February 4, 2016 a preliminary non-binding proposal ... of PKU V-Ming ( Shanghai ) Investment ... Development ( Shenzhen ) Fund Management Co., ...
Breaking Biology Technology:
(Date:2/2/2016)... 2016 Checkpoint Inhibitors for Cancer – ... Are you interested in the future of cancer ... inhibitors. Visiongain,s report gives those predictions to 2026 ... level. Avoid falling behind in data or ... revenues those emerging cancer therapies can achieve. There ...
(Date:2/1/2016)... -- Today, the first day of American Heart Month, the ... first of its kind workplace health solution that leverages ... first application of Watson to ... Welltok will create a new offering that combines AHA,s ... on Welltok,s health optimization platform. The effort is intended ...
(Date:1/25/2016)... 25, 2016  Glencoe Software, the world-leading supplier of ... industries, will provide the data management solution OMERO Plus ... Photo - ... Phenotypic analysis measures the characteristics and ... comparisons between states such as health and disease, the ...
Breaking Biology News(10 mins):